An Open-Label Study To Evaluate D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562, Using Positron Emission Tomography (PET) With Ligand [18F]MNI-968 in Healthy Male Subjects
Phase of Trial: Phase 0
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs PF 6412562 (Primary)
- Indications Cognition disorders; Parkinson's disease; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Invicro
- 18 Apr 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2018 New trial record